EVIO Inc. (EVIO) Expanding into Biosciences with a
Post# of 2022
(Total Views: 129)
Posted On: 06/05/2018 6:10:47 PM
EVIO Inc. (EVIO) Expanding into Biosciences with a Focus on Cannabis and Cannabinoid Research
- EVIO Biosciences Division will research and develop new medical cannabis therapies
- New division will be headed by the company’s chief science officer, Dr. Anthony Smith
- EVIO CEO and co-founder to present at key microcap investor conference
As an established leader in cannabis testing in the United States and Canada, EVIO Inc. (OTCQB: EVIO) is more familiar than most with the knowns and unknowns of medical cannabis. The company is now maximizing its technical know-how and experience by expanding into the research and development of cannabis-based medicines.
In a press release issued on May 24, EVIO unveiled the launch of its Biosciences Division. This new division will focus its efforts on exploring medical therapies of cannabis, including developing new formulations and researching more effective ways to deliver cannabis into the body (http://nnw.fm/e3ULT).
Marijuana deregulation is snowballing around the world, and, as cannabis becomes more accessible, there is an increasing demand, need and opportunity for solid scientific research into its potential uses and benefits, as well as its interactions with various medications. A key focus of EVIO’s Bioscience Division will be researching how cannabis can be used in combination with other medicines.
EVIO Chief Science Officer Dr. Anthony Smith will head the new division. He holds a PhD from Oregon State University in molecular and cellular biology, with biochemistry, metabolism and nutrition as his areas of specialty, and he brings more than 15 years of experience to EVIO Biosciences.
In a news release, Smith said, “We are expanding the life sciences part of the company to focus on the need for bioscience applications in cannabis, in addition to analytical testing services. We are focusing on scientific research to support biotechnology and IP development for advanced formulation, manufacturing and delivery processes. One exciting project is developing cannabinoid receptor (CB1 & CB2) biochemistry models aimed at discovering the future of cannabis medicine. The real benefit will be leveraging our R&D in partnership with medical and healthcare providers to bring solutions to real world health problems.”
With the company poised to branch out into this largely untapped field, EVIO co-founder and CEO William Waldrop will be meeting investors and presenting at the LD Micro Invitational conference in California on June 5. The conference, which will take place in Bel Air, will give prospective investors the opportunity to learn more about the company (http://nnw.fm/Q6hpP).
“The cannabis testing market is projected to reach $1.4 billion by 2021 and EVIO is well-positioned to capitalize on this tremendous growth in North America as Canada legalizes recreational use and states mandate testing of products from accredited laboratories,” Waldrop noted in a news release. “We look forward to educating LD Micro attendees on our services and the opportunities we offer to both businesses and investors.”
Several states require that cannabis for medical consumption is tested, and EVIO is already an accredited and established leader in providing testing services for the regulated cannabis industry. Its areas of work include screening and analysis, quality assurance and consulting services in a variety of areas, including formula and dose standardization and research and development. The company currently operates 11 testing labs in California, Florida, Oregon, Massachusetts, Colorado and Canada, and it is on track to have 18 such facilities by the end of the year.
For more information, visit the company’s website at www.EVIOLabs.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- EVIO Biosciences Division will research and develop new medical cannabis therapies
- New division will be headed by the company’s chief science officer, Dr. Anthony Smith
- EVIO CEO and co-founder to present at key microcap investor conference
As an established leader in cannabis testing in the United States and Canada, EVIO Inc. (OTCQB: EVIO) is more familiar than most with the knowns and unknowns of medical cannabis. The company is now maximizing its technical know-how and experience by expanding into the research and development of cannabis-based medicines.
In a press release issued on May 24, EVIO unveiled the launch of its Biosciences Division. This new division will focus its efforts on exploring medical therapies of cannabis, including developing new formulations and researching more effective ways to deliver cannabis into the body (http://nnw.fm/e3ULT).
Marijuana deregulation is snowballing around the world, and, as cannabis becomes more accessible, there is an increasing demand, need and opportunity for solid scientific research into its potential uses and benefits, as well as its interactions with various medications. A key focus of EVIO’s Bioscience Division will be researching how cannabis can be used in combination with other medicines.
EVIO Chief Science Officer Dr. Anthony Smith will head the new division. He holds a PhD from Oregon State University in molecular and cellular biology, with biochemistry, metabolism and nutrition as his areas of specialty, and he brings more than 15 years of experience to EVIO Biosciences.
In a news release, Smith said, “We are expanding the life sciences part of the company to focus on the need for bioscience applications in cannabis, in addition to analytical testing services. We are focusing on scientific research to support biotechnology and IP development for advanced formulation, manufacturing and delivery processes. One exciting project is developing cannabinoid receptor (CB1 & CB2) biochemistry models aimed at discovering the future of cannabis medicine. The real benefit will be leveraging our R&D in partnership with medical and healthcare providers to bring solutions to real world health problems.”
With the company poised to branch out into this largely untapped field, EVIO co-founder and CEO William Waldrop will be meeting investors and presenting at the LD Micro Invitational conference in California on June 5. The conference, which will take place in Bel Air, will give prospective investors the opportunity to learn more about the company (http://nnw.fm/Q6hpP).
“The cannabis testing market is projected to reach $1.4 billion by 2021 and EVIO is well-positioned to capitalize on this tremendous growth in North America as Canada legalizes recreational use and states mandate testing of products from accredited laboratories,” Waldrop noted in a news release. “We look forward to educating LD Micro attendees on our services and the opportunities we offer to both businesses and investors.”
Several states require that cannabis for medical consumption is tested, and EVIO is already an accredited and established leader in providing testing services for the regulated cannabis industry. Its areas of work include screening and analysis, quality assurance and consulting services in a variety of areas, including formula and dose standardization and research and development. The company currently operates 11 testing labs in California, Florida, Oregon, Massachusetts, Colorado and Canada, and it is on track to have 18 such facilities by the end of the year.
For more information, visit the company’s website at www.EVIOLabs.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)EVIO Inc (EVIO) Stock Research Links
Scroll down for more posts ▼